Aimmune Therapeutics Inc (NASDAQ:AIMT) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Monday.

According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “

Several other equities research analysts also recently commented on AIMT. Piper Jaffray Companies dropped their target price on Aimmune Therapeutics to $38.00 in a report on Wednesday, March 15th. Wedbush reissued an “outperform” rating and issued a $42.00 target price on shares of Aimmune Therapeutics in a report on Wednesday, February 8th. One analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Aimmune Therapeutics presently has a consensus rating of “Buy” and an average target price of $33.60.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Shares of Aimmune Therapeutics (NASDAQ:AIMT) traded up 0.80% during midday trading on Monday, reaching $22.61. The company had a trading volume of 261,580 shares. The stock’s market capitalization is $958.26 million. The company’s 50-day moving average is $20.11 and its 200-day moving average is $19.52. Aimmune Therapeutics has a 1-year low of $9.77 and a 1-year high of $27.31.

Aimmune Therapeutics (NASDAQ:AIMT) last released its earnings results on Wednesday, March 15th. The company reported ($0.55) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by $0.08. On average, equities research analysts forecast that Aimmune Therapeutics will post ($2.80) EPS for the current year.

Your IP Address:

A number of large investors have recently added to or reduced their stakes in AIMT. TD Asset Management Inc. increased its position in shares of Aimmune Therapeutics by 136.7% in the third quarter. TD Asset Management Inc. now owns 31,478 shares of the company’s stock worth $472,000 after buying an additional 18,178 shares during the last quarter. Victory Capital Management Inc. acquired a new position in shares of Aimmune Therapeutics during the third quarter worth about $579,000. Wells Fargo & Company MN increased its position in shares of Aimmune Therapeutics by 6.7% in the third quarter. Wells Fargo & Company MN now owns 54,933 shares of the company’s stock worth $824,000 after buying an additional 3,454 shares during the last quarter. Columbus Circle Investors acquired a new position in shares of Aimmune Therapeutics during the third quarter worth about $918,000. Finally, Norges Bank acquired a new position in shares of Aimmune Therapeutics during the fourth quarter worth about $1,258,000. 61.61% of the stock is currently owned by institutional investors and hedge funds.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, formerly Allergen Research Corporation, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

5 Day Chart for NASDAQ:AIMT

Get a free copy of the Zacks research report on Aimmune Therapeutics (AIMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aimmune Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.